Ovarian cancer (BRCA-mutated)
- Platinum sensitivity is often high
- PARP inhibitors exploit homologous-recombination deficiency
- Maintenance PARP therapy is important in selected settings
- Benefit/risk depends on prior therapy + disease context
- Monitor cytopenias and rare MDS/AML risk
- Germline BRCA finding requires family/genetic counseling
Use at a glance
- Platinum sensitivity is often high
Choosing treatment
- Maintenance PARP therapy is important in selected settings
Practical pearls
- PARP inhibitors exploit homologous-recombination deficiency
- Germline BRCA finding requires family/genetic counseling
Monitoring / follow-up
- Benefit/risk depends on prior therapy + disease context
- Monitor cytopenias and rare MDS/AML risk
Self-check
- What should be monitored during treatment of Ovarian cancer (BRCA-mutated)?
cytopenias and rare MDS/AML risk.
- What is required when Germline BRCA finding occurs in Ovarian cancer (BRCA-mutated)?
family/genetic.
Drugs used for this (1)
All clinical uses · Open the interactive console ↗
